RxDoctor Payments Data

Pamela Williams

Family · Cullman, ALNPI 1407871254

Payments from drug & device makers

$470in general payments, 2019–2025

Across 27 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$119
  • AbbVie$78
  • Astellas Pharma US Inc$73
  • Sanofi-aventis U.S. LLC$38
  • Amgen$35
  • AstraZeneca$34
  • plus $93 from 4 others

What the payments were for

  • Food & beverage$470100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$470 in reported general payments places this provider in the 50th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$88,894
Medicare patients
218
Services billed
3,097

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban72$69,497
OzempicSemaglutide52$61,613
JanuviaSitagliptin Phosphate60$46,964
MounjaroTirzepatide38$38,753
JardianceEmpagliflozin35$38,053
FarxigaDapagliflozin Propanediol31$28,660
XareltoRivaroxaban21$24,157
TrulicityDulaglutide11$24,020
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$22,853
MyrbetriqMirabegron23$20,225
Breo ElliptaFluticasone/Vilanterol38$15,174
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$5,466
Levothyroxine Sodium270$4,074
Celecoxib67$3,857
Omega-3 Acid Ethyl Esters24$3,784

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$33$69,49772 claims
Novo NordiskOzempic$119$61,61352 claims
GSKTrelegy Ellipta, Breo Ellipta$13$38,02760 claims
AstraZenecaFarxiga$34$28,66031 claims
Astellas Pharma US IncMyrbetriq$73$20,22523 claims
AbbVieSynthroid$78$1,93628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 3,415 family providers in Alabama.

Other family in Cullman

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →